

Nexstim

Nexstim Receives NBS System 5 Order from New European Customer

Press release, Helsinki, 10 July 2024 at 9 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 through a distributor in Europe. The end customer is acquiring the system primarily for research purposes.

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The NBS System 5 provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. The system ordered also includes a therapy module, allowing the system to be used for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: *"Happy to announce this order and to welcome a new hospital customer to our user community. We are proud to provide our customers with access to an international research network, and to have an active user base also when it comes to research use of our systems."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com